CagriSema
Also known as: cagrilintide + semaglutide
Browse our CagriSema articles and comparisons. Start with the drug explainer for the mechanism and trial evidence, or choose a comparison below.
Profile at a glance
| Attribute | Value |
|---|---|
| Sponsor | Novo Nordisk |
| Mechanism | GLP-1 + amylin (fixed-dose combination) |
| Administration | Once-weekly subcutaneous injection |
| Peak weight loss | ~20.4% at 68 weeks (REDEFINE 1) |
| Status | NDA filed December 2025 — regulatory decision expected 2026 |
Drug explainer
What Is CagriSema? Novo Nordisk's Amylin + GLP-1 Weight Loss Combination →The investigational cagrilintide–semaglutide combination: REDEFINE results, side effects and the status of FDA review.
CagriSema compared
Comparisons involving CagriSema, with the limits of comparing separate trials.
Retatrutide vs CagriSema (Cagrilintide + Semaglutide): Triple Agonist vs Amylin + GLP-1 Combo
Compare retatrutide with the cagrilintide–semaglutide combination, including REDEFINE 4 and why separate trial results do not establish superiority.
Updated September 8, 2026
CagriSema vs Tirzepatide (Zepbound): REDEFINE 4 Head-to-Head Results
REDEFINE 4 reported 23.0% versus 25.5% weight loss under the efficacy estimand and did not meet its non-inferiority endpoint.
Updated September 8, 2026
Cagrilintide and Tirzepatide: Stacking Amylin With a Dual Agonist
Evidence for this specific combination is preclinical. CagriSema and eloralintide trials cannot establish a cagrilintide–tirzepatide dosing plan.
Updated September 8, 2026
Related articles
Safety, mechanism, and context pieces that reference CagriSema.
What Is Cagrilintide? The Amylin Analog Behind CagriSema
An investigational amylin analog studied alone and with semaglutide in CagriSema; trial results and current development explained.
Updated September 8, 2026
Dave Knapp on CagriSema vs Tirzepatide, Novo Nordisk's Triple Agonist UBT-251, and Retatrutide: Fact Check
Dave Knapp’s CagriSema, UBT251 and pricing coverage: accurate headline figures, with unproven patient-selection and strategy claims distinguished.
Updated September 8, 2026
See all drug profiles in the drug profiles hub or compare drugs head-to-head in the comparisons hub.